Figure 5

Cellular and serum miR-150 across disease evolution. (A, B) Evolution of cellular and serum miR-150, respectively, in seven different patients according to lymphocytosis evolution. Cellular (C) and serum (D) miR-150 level were compared in paired samples of the same patient at diagnosis and after relapse (n = 8). (E) Serum miR-150 level was compared in paired samples from the same patients at diagnosis and after molecular remission (n = 7). The Wilcoxon matched pairs nonparametric test was used to calculate significant differences.